Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Implantable defibrillators. Clinical experience].

M Mirowski, M M Mower, E P Veltri

    Annales De Cardiologie Et D'Angeiologie
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Is the ABCB1 gene associated with the increased risk of gastric cancer development?--preliminary research.

    Pathology, research and practice·2014
    Same author

    Quantitative analysis of the p65 gene expression in patients with coloroctal cancer.

    International journal of biomedical science : IJBS·2013
    Same author

    Influence of antibiotic therapy on the level of selected angiogenic factors in patients with benign gynecologic tumors--preliminary report.

    Die Pharmazie·2011
    Same author

    Release kinetics of basic fibroblast growth factor (bFGF) from certain biopolymers in the presence of ketoprofen.

    Die Pharmazie·2010
    Same author

    Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center Collaborative Study.

    Journal of drug targeting·2010
    Same author

    Maspin and Nm23-H1 expression in colorectal cancer.

    Neoplasma·2010
    Same journal

    [Study of Sleep Apnea Syndrome in Patients with Chronic Heart Failure in the Cardiology Department at Yalgado Ouédraogo teaching hospital in 2024 and 2025].

    Annales de cardiologie et d'angeiologie·2026
    Same journal

    [Impact of knowledge and practices of hygieno-dietetical measures in hypertensive people at the Abidjan cardiology institute].

    Annales de cardiologie et d'angeiologie·2026
    Same journal

    [Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

    Annales de cardiologie et d'angeiologie·2026
    Same journal

    [Dobutamine stress echocardiography: Appropriateness of indications and protocol compliance. A single-centre report].

    Annales de cardiologie et d'angeiologie·2026
    Same journal

    [Post-COVID postural orthostatic tachycardia syndrome: Documentation of a hyperadrenergic phenotype by comprehensive autonomic testing].

    Annales de cardiologie et d'angeiologie·2026
    Same journal

    Urban-rural disparities in hypertension prevalence, screening, and control in South Kivu Province, eastern Democratic Republic of the Congo.

    Annales de cardiologie et d'angeiologie·2026
    See all related articles

    This article reviews the clinical performance of a specialized device designed to detect and treat dangerous, irregular heart rhythms in patients who have survived sudden cardiac arrest. By automatically delivering electrical shocks when necessary, the device helps prevent fatal outcomes without requiring immediate human intervention. Data from hundreds of patients show that this technology significantly improves survival rates for those at high risk of life-threatening arrhythmias.

    Area of Science:

    • Cardiovascular medicine and Automatic Implantable Cardioverter-Defibrillator research
    • Electrophysiology and clinical outcomes analysis

    Background:

    No consensus exists regarding the long-term efficacy of automated rhythm-correcting hardware for high-risk cardiac patients. Prior research has shown that sudden cardiac arrest presents a severe threat to patient survival. That uncertainty drove clinicians to develop specialized hardware for continuous monitoring. This gap motivated the deployment of devices capable of identifying lethal electrical patterns. It was already known that rapid intervention is required to prevent death during these events. No prior work had resolved whether autonomous systems could reliably replace manual resuscitation efforts. That challenge prompted early testing of internal shock delivery systems in clinical settings. Researchers sought to determine if these units could effectively manage malignant heart rhythms over extended durations.

    Purpose Of The Study:

    This review aims to evaluate the clinical effectiveness of automated rhythm-correcting hardware in patients with malignant heart conditions. The investigation seeks to determine if these devices can reliably detect and treat life-threatening electrical events. Researchers intend to quantify the impact of internal shock delivery on long-term survival rates. The study addresses the challenge of managing patients who have survived previous episodes of sudden cardiac arrest. By examining extensive clinical experience, the authors hope to clarify the role of this technology in modern cardiology. The motivation stems from the need to overcome the inherent delays of traditional emergency resuscitation methods. This work explores whether autonomous systems provide a safer alternative for high-risk populations. The authors aim to synthesize current evidence to support the broader adoption of these life-saving units.

    Keywords:
    sudden cardiac deathventricular fibrillationcardiac rhythm monitoringelectrical discharge therapy

    Frequently Asked Questions

    The device continuously observes heart activity to detect dangerous electrical patterns. Once it identifies ventricular fibrillation or rapid tachycardias, it delivers an electrical discharge to reset the rhythm. This process restores normal heart function without requiring external medical staff or immediate manual intervention.

    The system utilizes an internal shock delivery mechanism to correct arrhythmias. Unlike traditional external defibrillators, this unit remains permanently inside the patient to provide immediate, autonomous response to cardiac emergencies, thereby removing the time delays inherent in conventional out-of-hospital resuscitation.

    The researchers indicate that the device is necessary for patients who have already survived sudden cardiac death. This specific population faces a high risk of recurrent, malignant arrhythmias, making continuous, automated monitoring a vital component of their long-term clinical management strategy.

    Related Experiment Videos

    Main Methods:

    The review approach synthesized data from over 800 patients who received rhythm-correcting hardware. Investigators examined long-term monitoring records to evaluate device performance during episodes of ventricular fibrillation. The analysis focused on comparing outcomes between patients treated with these units and historical survival benchmarks. Researchers gathered information from multiple medical institutions to ensure a comprehensive assessment of therapeutic success. This investigation utilized consecutive case series to minimize selection bias during the evaluation period. The study design prioritized tracking mortality rates specifically linked to cardiac electrical instability. Experts reviewed the technical capabilities of the hardware in identifying life-threatening tachycardias. The methodology emphasized the transition from experimental application to established clinical practice for high-risk individuals.

    Main Results:

    The strongest finding indicates that the device reduces arrhythmic mortality to 1.7% over a one-year period. Data from 130 consecutive patients at a single institution support this high level of efficacy. These results align with outcomes reported by other medical centers globally. The hardware successfully identifies and terminates dangerous tachycardias without human assistance. By eliminating time constraints, the system prevents the delays often seen in conventional resuscitation. Total mortality rates for the implantees show a significant decrease compared to pre-implantation baselines. The technology effectively restores normal cardiac action through precise electrical discharges. These findings demonstrate that automated internal intervention provides a robust defense against sudden cardiac death.

    Conclusions:

    The authors suggest that internal rhythm-correcting hardware provides a reliable solution for managing malignant heart conditions. Evidence indicates that these systems successfully lower the frequency of fatal outcomes among high-risk populations. Data from multiple medical centers confirm that survival rates remain high following the placement of these units. The findings imply that autonomous shock delivery effectively bypasses the limitations of traditional emergency response. No evidence suggests that manual resuscitation remains superior for these specific patients. The researchers propose that widespread adoption could further decrease mortality across similar cohorts. Synthesis of the available literature confirms the safety and utility of this technology in practice. These observations support the continued use of automated devices for patients prone to life-threatening electrical instability.

    Clinical data from 130 consecutive patients at The Johns Hopkins Hospital provided the primary evidence. This cohort allowed researchers to track one-year mortality outcomes, which reached a low of 1.7% due to arrhythmias, demonstrating the effectiveness of the hardware in a real-world setting.

    The measurement focused on the one-year mortality rate specifically attributed to arrhythmias. By comparing these figures to broader clinical reports, the authors established that the device consistently reduces death rates across different medical centers, confirming its reliability as a therapeutic intervention.

    The authors propose that the growing body of clinical experience confirms a marked reduction in mortality for those receiving the device. They suggest that this technology effectively addresses the limitations of conventional resuscitation, providing a superior alternative for preventing sudden death in high-risk individuals.